HRAS and urinary bladder carcinoma: Given the crucial role of HRAS overexpression and mutations in the tumorigenesis of bladder cancer, one attractive therapeutic strategy could be to inhibit HRAS transcription with molecules that are able to impair the activity of the gene promoter.